8-K: SelectQuote Secures $350 Million Investment Through Preferred Stock and Warrant Issuance

SelectQuote completed a $350 million investment deal by issuing preferred stock and warrants to NL Monarch Holdings LLC (Morgan Stanley) and NL Monarch Holdings II LLC (Bain).

Summary

• SelectQuote, Inc. finalized a $350 million investment on February 28, 2025, through the sale of Senior Non-Convertible Preferred Stock and warrants to NL Monarch Holdings LLC (Morgan Stanley) and NL Monarch Holdings II LLC (Bain).
• The company issued 350,000 shares of Preferred Stock with a face value of $1,000 per share, along with 30,833,333 warrants to purchase common stock.
• Each investor, Morgan Stanley and Bain, contributed $175 million and received 175,000 shares of Preferred Stock and warrants for various tranches of common stock.
• The warrants include Tranche A (6,740,740.5 shares at $0.01 exercise price), Tranche B (5,055,555.5 shares with exercise price between $2.15 and $4.00), and Tranche C (3,620,370.5 shares at $5.50 exercise price).
• Dividends on the Preferred Stock will accrue daily at an initial rate of 14.5% per annum, payable quarterly, with potential adjustments based on the company's liquidity and debt levels.
• The Preferred Stock ranks senior to common stock and other equivalents, with specific protective provisions requiring investor consent for key corporate actions.
• The company may redeem up to 50,000 shares of Preferred Stock between December 1 and December 31, 2025, at 114.5% of the Original Liquidation Preference.
• After the sixth anniversary of the issue date, the company can redeem all or part of the Preferred Stock at the Original Liquidation Preference plus accrued dividends.
• Holders of Preferred Stock have a put right after six years, allowing them to require the company to redeem their shares at the Redemption Price.
• The agreement includes provisions for a liquidity process if the company fails to redeem the Preferred Stock, potentially leading to a sale of the company.
• Two new directors, Srdjan Vukovic and Christopher Wolfe, were appointed to the Board of Directors as part of the agreement.

Sentiment

Score: 6

Explanation: The document indicates a significant capital infusion, which is generally positive. However, the high dividend rate and protective provisions suggest potential constraints on the company's future operations, resulting in a neutral to slightly positive sentiment.

Positives

• The $350 million investment provides SelectQuote with substantial capital to support its operations and strategic initiatives.
• The potential decrease in the dividend rate to 13.5% if certain financial conditions are met could reduce the company's cost of capital.
• The appointment of experienced directors like Srdjan Vukovic and Christopher Wolfe could enhance the company's governance and strategic decision-making.
• The put right provides the investors with a mechanism to exit their investment after six years if the company's performance does not meet their expectations.

Negatives

• The high initial dividend rate of 14.5% on the Preferred Stock represents a significant ongoing expense for the company.
• The protective provisions grant significant control to the investors, potentially limiting the company's flexibility in making strategic decisions.
• The potential for an increased dividend rate of up to 20% during a Liquidity Period could further strain the company's finances.
• The possibility of a forced liquidity transaction if the company fails to redeem the Preferred Stock could be disruptive.

Risks

• The company's ability to meet the financial conditions required to reduce the dividend rate is uncertain.
• The Credit Agreement and other debt obligations could restrict the company's ability to redeem the Preferred Stock.
• The investors' consent rights could delay or prevent the company from pursuing certain strategic opportunities.
• A Preferred Default could trigger a liquidity crisis and force the company to pursue a sale or other restructuring.

Future Outlook

The document outlines potential liquidity transactions and redemption scenarios, indicating a focus on managing the Preferred Stock and warrant obligations. The company's future financial performance will determine the actual dividend rates and redemption possibilities.

Industry Context

This investment reflects private equity firms' continued interest in the insurance and healthcare sectors, particularly in companies with strong growth potential but requiring capital to navigate current market conditions. Similar deals have been observed with other insurance distributors and healthcare service providers.

Comparison to Industry Standards

• The dividend rate of 14.5% on the preferred stock is relatively high compared to standard debt financing, reflecting the risk profile of SelectQuote and the negotiated terms with the investors.
• Similar transactions in the insurance brokerage industry, such as the recapitalization of Confie Seguros by Stone Point Capital, have involved a mix of debt and equity to optimize the capital structure.
• The warrant structure is a common feature in private equity investments, providing investors with potential upside from future stock appreciation, similar to warrants issued in connection with Silver Lake's investment in Expedia Group.
• The protective provisions and consent rights granted to the investors are typical in preferred stock agreements, ensuring that the investors have a say in key corporate decisions, comparable to the rights granted to preferred shareholders in KKR's investment in Bright Health.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Dilution from potential warrant exercises, but also benefit from the company's increased financial stability.
• Employees: Increased job security due to the company's improved financial position.
• Customers: No immediate impact, but potential for improved services and products due to the company's increased investment capacity.
• Suppliers: Increased business opportunities due to the company's improved financial position.
• Creditors: Enhanced creditworthiness of the company due to the capital infusion.

Next Steps

• The company will issue the balance of the aggregate Warrants that are allocated to each Purchaser on January 2, 2026, subject to potential reductions based on early redemption of Preferred Stock.
• The company will need to manage its liquidity and debt levels to potentially reduce the dividend rate on the Preferred Stock.
• The company will need to comply with the protective provisions and obtain investor consent for certain key corporate actions.
• The company may explore options for redeeming the Preferred Stock after December 1, 2025, or after the sixth anniversary of the issue date.

Key Dates